Archive for May 10th, 2012

ARNA positive Adcom vote. APPA NDA due mid-2012. PATH to resubmit NDA 3Q + TZYM OMER BIOD CTIC MNOV ANAC PBTH updates

May 10, 2012 No Comments by

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4, with one abstention, to recommend approval of lorcaserin in patients with obesity. The current PDUFA date is June 27, 2012. However, this may be extended by three months if further data is provided by the company. A.P. Pharma, Inc.(OTCBB:APPA.OB) […]

Daily News Read more

VTUS Phase 3 data due May. SCMP sNDA filing soon + Pipeline updates for ASTM OXGN RVX IDRA ARIA

May 10, 2012 No Comments by

Ventrus Biosciences, Inc. (Nasdaq:VTUS) gave a pipeline update noting that initial top-line data from its Phase 3 trial of Diltiazem (VEN 307) in patients with Anal Fissures, is expected to be available in May 2012. Phase 3 data of Iferanserin (VEN 309) in patients with Hemorrhoidal Disease, is expected in late June or early July 2012. Aastrom Biosciences, Inc. (Nasdaq:ASTM) […]

Daily News Read more